

# Richard Troughton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1189475/publications.pdf>

Version: 2024-02-01

121  
papers

8,716  
citations

66250

44  
h-index

49824

91  
g-index

123  
all docs

123  
docs citations

123  
times ranked

9791  
citing authors

#	ARTICLE	IF	CITATIONS
1	A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 743-755.	1.3	9
2	Reduced Exercise Capacity in Adults Born at Very Low Birth Weight: A Population-based Cohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 88-98.	2.5	12
3	Relationship Between Soluble Transferrin Receptor and Clinical Outcomes in Patients With Heart Failure According to Ejection Fraction Phenotype: The New Zealand PEOPLE Study. <i>Journal of Cardiac Failure</i> , 2022, 28, 1255-1263.	0.7	12
4	Circulating levels and prognostic cutoffs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2084-2095.	1.4	15
5	The Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS): Design and Methodology. <i>Neurology International</i> , 2021, 11, 84-97.	0.2	3
6	Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. <i>ESC Heart Failure</i> , 2021, 8, 4572-4583.	1.4	21
7	NT-proBNP for Risk Prediction in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 653-663.	1.9	20
8	Low miR-19b-1 Expression Is Related to Aspirin Resistance and Major Adverse Cardio-Cerebrovascular Events in Patients With Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2021, 10, e017120.	1.6	11
9	Right Ventricular Structure and Function in Young Adults Born Preterm at Very Low Birth Weight. <i>Journal of Clinical Medicine</i> , 2021, 10, 4864.	1.0	3
10	Cardiac structure and function in very preterm-born adolescents compared to term-born controls: A longitudinal cohort study. <i>Early Human Development</i> , 2021, 163, 105505.	0.8	3
11	Neonatal oxygen saturation alarm compliance – under recognized source of iatrogenic harm? An audit and survey of nursing opinion. <i>Journal of Neonatal Nursing</i> , 2020, 26, 43-48.	0.3	4
12	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020, 22, 2078-2088.	2.9	26
13	Mid-regional proadrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation. <i>European Journal of Heart Failure</i> , 2020, 22, 692-700.	2.9	11
14	Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics. <i>Circulation</i> , 2020, 142, 1408-1421.	1.6	50
15	Circulating Forms of B-Type Natriuretic Peptide in Very Preterm Infants. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 506-515.	0.6	1
16	Cardiovascular Outcomes in Young Adulthood in a Population-Based Very Low Birth Weight Cohort. <i>Journal of Pediatrics</i> , 2020, 225, 74-79.e3.	0.9	24
17	Analytical and biological assessment of circulating human erythroferrone. <i>Clinical Biochemistry</i> , 2020, 79, 41-47.	0.8	13
18	Early kinetic profiles of troponin I and T measured by high-sensitivity assays in patients with myocardial infarction. <i>Clinica Chimica Acta</i> , 2020, 505, 15-25.	0.5	28

#	ARTICLE	IF	CITATIONS
19	An RCT of brief cognitive therapy versus treatment as usual in patients with non-cardiac chest pain. <i>International Journal of Cardiology</i> , 2019, 289, 6-11.	0.8	13
20	Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals. <i>Clinical Biochemistry</i> , 2019, 69, 36-44.	0.8	28
21	Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 1733-1738.	2.9	23
22	Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1300-1313.	1.2	68
23	Prognostic Implications of Dual Platelet Reactivity Testing in Acute Coronary Syndrome. <i>Thrombosis and Haemostasis</i> , 2018, 118, 415-426.	1.8	5
24	Combining High-Sensitivity Cardiac Troponin I and Cardiac Troponin T in the Early Diagnosis of Acute Myocardial Infarction. <i>Circulation</i> , 2018, 138, 989-999.	1.6	56
25	Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. <i>European Heart Journal</i> , 2018, 39, 1770-1780.	1.0	194
26	Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus. <i>European Journal of Pediatrics</i> , 2018, 177, 521-532.	1.3	27
27	Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study. <i>European Journal of Heart Failure</i> , 2018, 20, 474-480.	2.9	19
28	A Risk Assessment Score and Initial High-Sensitivity Troponin Combine to Identify Low Risk of Acute Myocardial Infarction in the Emergency Department. <i>Academic Emergency Medicine</i> , 2018, 25, 434-443.	0.8	12
29	ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome). <i>Circulation</i> , 2018, 137, 354-363.	1.6	32
30	Validity of a Novel Point-of-Care Troponin Assay for Single-Test Rule-Out of Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 1108.	3.0	60
31	Detectable High-Sensitivity Cardiac Troponin within the Population Reference Interval Conveys High 5-Year Cardiovascular Risk: An Observational Study. <i>Clinical Chemistry</i> , 2018, 64, 1044-1053.	1.5	33
32	Plasma Ceramides as Prognostic Biomarkers and Their Arterial and Myocardial Tissue Correlates in Acute Myocardial Infarction. <i>JACC Basic To Translational Science</i> , 2018, 3, 163-175.	1.9	64
33	Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department. <i>Cmaj</i> , 2018, 190, E974-E984.	0.9	38
34	Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection. <i>Annals of Internal Medicine</i> , 2017, 166, 715.	2.0	231
35	C-Type Natriuretic Peptides in Coronary Disease. <i>Clinical Chemistry</i> , 2017, 63, 316-324.	1.5	25
36	Deciphering a macro-troponin I complex; a case report. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, e77-e79.	1.4	10

#	ARTICLE	IF	CITATIONS
37	Superior performance of N-terminal pro brain natriuretic peptide for diagnosis of acute decompensated heart failure in an Asian compared with a Western setting. <i>European Journal of Heart Failure</i> , 2017, 19, 209-217.	2.9	32
38	A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012. <i>New Zealand Medical Journal</i> , 2017, 130, 17-28.	0.5	3
39	Favorable 5-Year Outcome of 21 Takotsubo Stress Cardiomyopathy Cases Triggered by an Earthquake. <i>Journal of the American College of Cardiology</i> , 2016, 68, 877.	1.2	1
40	B-type natriuretic peptide signal peptide (BNPsp) in patients presenting with chest pain. <i>Clinical Biochemistry</i> , 2016, 49, 645-650.	0.8	6
41	Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. <i>European Journal of Heart Failure</i> , 2015, 17, 1252-1261.	2.9	95
42	Human muscle sympathetic nerve responses to urocortin <sub>2</sub> in health and stable heart failure. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 888-895.	0.9	4
43	CNP Signal Peptide in Patients with Cardiovascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2015, 2, 28.	1.1	9
44	Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). <i>Journal of Cardiac Failure</i> , 2015, 21, 479-488.	0.7	69
45	Accelerated diagnostic protocol using high-sensitivity cardiac troponin T in acute chest pain patients. <i>International Journal of Cardiology</i> , 2015, 184, 208-215.	0.8	46
46	Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 656-665.	2.3	182
47	The utility of presentation and 4-hour high sensitivity troponin I to rule-out acute myocardial infarction in the emergency department. <i>Clinical Biochemistry</i> , 2015, 48, 1219-1224.	0.8	11
48	A novel troponin T peptide in humans: Assay, biochemistry and preliminary findings in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2015, 190, 68-74.	0.8	3
49	Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study. <i>PLoS ONE</i> , 2014, 9, e114969.	1.1	184
50	Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. <i>European Heart Journal</i> , 2014, 35, 1559-1567.	1.0	229
51	Development and validation of the emergency department assessment of chest pain score and 2-hour accelerated diagnostic protocol. <i>EMA - Emergency Medicine Australasia</i> , 2014, 26, 34-44.	0.5	172
52	Comparison of new point-of-care troponin assay with high sensitivity troponin in diagnosing myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 177, 182-186.	0.8	30
53	Natriuretic peptide-guided heart failure management. <i>European Heart Journal</i> , 2014, 35, 16-24.	1.0	159
54	Comparison of high sensitivity troponin T and I assays in the diagnosis of non-ST elevation acute myocardial infarction in emergency patients with chest pain. <i>Clinical Biochemistry</i> , 2014, 47, 321-326.	0.8	32

#	ARTICLE	IF	CITATIONS
55	A 2-Hour Diagnostic Protocol for Possible Cardiac Chest Pain in the Emergency Department. <i>JAMA Internal Medicine</i> , 2014, 174, 51.	2.6	151
56	Circulating miR-323-3p and miR-652: Candidate markers for the presence and progression of acute coronary syndromes. <i>International Journal of Cardiology</i> , 2014, 176, 375-385.	0.8	40
57	Natriuretic Peptides in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2014, 10, 453-470.	1.0	27
58	Genetic Polymorphism rs6922269 in the MTHFD1L Gene Is Associated with Survival and Baseline Active Vitamin B12 Levels in Post-Acute Coronary Syndromes Patients. <i>PLoS ONE</i> , 2014, 9, e89029.	1.1	12
59	Urocortin-2 Infusion in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 433-441.	1.9	47
60	The Singapore Heart Failure Outcomes and Phenotypes (SHOP) Study and Prospective Evaluation of Outcome in Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PEOPLE) Study: Rationale and Design. <i>Journal of Cardiac Failure</i> , 2013, 19, 156-162.	0.7	61
61	Comparison of immunoassays for NTproBNP conducted on three analysis systems: Milliplex, Elecsys and RIA. <i>Clinical Biochemistry</i> , 2013, 46, 388-390.	0.8	10
62	Validation of High-Sensitivity Troponin I in a 2-Hour Diagnostic Strategy to Assess 30-Day Outcomes in Emergency Department Patients With Possible Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1242-1249.	1.2	277
63	Examining Renal Impairment as a Risk Factor for Acute Coronary Syndrome: A Prospective Observational Study. <i>Annals of Emergency Medicine</i> , 2013, 62, 38-46.e1.	0.3	11
64	Are Serial BNP Measurements Useful in Heart Failure Management?. <i>Circulation</i> , 2013, 127, 500-508.	1.6	124
65	Characterization and Prediction of Natriuretic Peptide a€œNonresponsea€œ During Heart Failure Management: Results From the Pro<sc>BNP</sc> Outpatient Tailored Chronic Heart Failure (<sc>PROTECT</sc>) and the <sc>NT</sc>a€œpro<sc>BNP</sc>a€œ Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (<sc>BATTLESCARRED</sc>) Study. <i>Congestive Heart Failure</i> , 2013, 19, 135-142.	2.0	39
66	Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. <i>European Journal of Heart Failure</i> , 2013, 15, 1138-1147.	2.9	147
67	Genetic variation in the reninâ€œangiotensinâ€œaldosterone system is associated with cardiovascular risk factors and early mortality in established coronary heart disease. <i>Journal of Human Hypertension</i> , 2013, 27, 237-244.	1.0	20
68	Acute Myocardial Infarction and Stress Cardiomyopathy following the Christchurch Earthquakes. <i>PLoS ONE</i> , 2013, 8, e68504.	1.1	64
69	Diagnostic and prognostic utility of early measurement with high-sensitivity troponin T assay in patients presenting with chest pain. <i>Cmaj</i> , 2012, 184, E260-E268.	0.9	68
70	Use of Natriuretic Peptides to Guide and Monitor Heart Failure Therapy. <i>Clinical Chemistry</i> , 2012, 58, 62-71.	1.5	36
71	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2012, 33, 1750-1757.	1.0	652
72	Association between endothelin type A receptor haplotypes and mortality in coronary heart disease. <i>Personalized Medicine</i> , 2012, 9, 341-349.	0.8	2

#	ARTICLE	IF	CITATIONS
73	High-sensitivity troponin T for early rule-out of myocardial infarction in recent onset chest pain. <i>Emergency Medicine Journal</i> , 2012, 29, 805-810.	0.4	47
74	Heart fatty acid binding protein and myoglobin do not improve early rule out of acute myocardial infarction when highly sensitive troponin assays are used. <i>Resuscitation</i> , 2012, 83, e27-e28.	1.3	11
75	ST2 Has Diagnostic and Prognostic Utility for All-Cause Mortality and Heart Failure in Patients Presenting to the Emergency Department With Chest Pain. <i>Journal of Cardiac Failure</i> , 2012, 18, 304-310.	0.7	52
76	A 2-hour thrombolysis in myocardial infarction score outperforms other risk stratification tools in patients presenting with possible acute coronary syndromes. <i>American Heart Journal</i> , 2012, 164, 516-523.	1.2	24
77	2-Hour Accelerated Diagnostic Protocol to Assess Patients With Chest Pain Symptoms Using Contemporary Troponins as the Only Biomarker. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2091-2098.	1.2	361
78	The Contrasting Relationships between Betaine and Homocysteine in Two Clinical Cohorts are Associated with Plasma Lipids and Drug Treatments. <i>PLoS ONE</i> , 2012, 7, e32460.	1.1	3
79	Betaine and Secondary Events in an Acute Coronary Syndrome Cohort. <i>PLoS ONE</i> , 2012, 7, e37883.	1.1	59
80	The Chromosome 9p21.3 Coronary Heart Disease Risk Allele Is Associated with Altered Gene Expression in Normal Heart and Vascular Tissues. <i>PLoS ONE</i> , 2012, 7, e39574.	1.1	37
81	KCNE5 Polymorphism rs697829 is Associated with QT Interval and Survival in Acute Coronary Syndromes Patients. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 319-324.	0.8	12
82	Loose tobacco, ethnicity, income and rurality. <i>Australian and New Zealand Journal of Public Health</i> , 2012, 36, 291-292.	0.8	1
83	A New Improved Accelerated Diagnostic Protocol Safely Identifies Low-Risk Patients With Chest Pain in the Emergency Department. <i>Academic Emergency Medicine</i> , 2012, 19, 510-516.	0.8	36
84	Serial Doppler Echocardiography and Tissue Doppler Imaging in the Detection of Elevated Directly Measured Left Atrial Pressure in Ambulant Subjects With Chronic Heart Failure. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 927-934.	2.3	78
85	Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 50, 695-701.	0.9	53
86	A Kaupapa Māori approach to a community cohort study of heart disease in New Zealand. <i>Australian and New Zealand Journal of Public Health</i> , 2011, 35, 249-255.	0.8	18
87	Community screening for cardiovascular risk factors and levels of treatment in a rural Māori cohort. <i>Australian and New Zealand Journal of Public Health</i> , 2011, 35, 517-523.	0.8	12
88	Genomic Risk Variants at 1p13.3, 1q41, and 3q22.3 Are Associated With Subsequent Cardiovascular Outcomes in Healthy Controls and in Established Coronary Artery Disease. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 636-646.	5.1	35
89	Physician-Directed Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart Failure. <i>Circulation</i> , 2010, 121, 1086-1095.	1.6	279
90	A Common Variant at Chromosome 9P21.3 Is Associated With Age of Onset of Coronary Disease but Not Subsequent Mortality. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 286-293.	5.1	44

#	ARTICLE	IF	CITATIONS
91	Plasma Corin Levels Provide Minimal Prognostic Utility Incremental to Natriuretic Peptides in Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 621-627.	0.7	13
92	Clinical Significance of Endogenous Vasoactive Neurohormones in Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 635-640.	0.7	20
93	Renal and cardiac function for long-term (10 year) risk stratification after myocardial infarction. <i>European Heart Journal</i> , 2009, 30, 1486-1494.	1.0	17
94	N-Terminal Pro-B-Type Natriuretic Peptide-Guided Treatment for Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 55, 53-60.	1.2	319
95	B-Type Natriuretic Peptides and Echocardiographic Measures of Cardiac Structure and Function. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 216-225.	2.3	65
96	Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort. <i>American Heart Journal</i> , 2008, 156, 752-758.	1.2	23
97	Ile164 variant of $\beta^2$ adrenoceptor does not influence outcome in heart failure but may interact with $\beta^2$ blocker treatment. <i>European Journal of Heart Failure</i> , 2008, 10, 55-59.	2.9	19
98	Angiotensinogen M235T and T174M Gene Polymorphisms in Combination Doubles the Risk of Mortality in Heart Failure. <i>Hypertension</i> , 2007, 49, 322-327.	1.3	49
99	The effects of medications on circulating levels of cardiac natriuretic peptides. <i>Annals of Medicine</i> , 2007, 39, 242-260.	1.5	47
100	BNP for Clinical Monitoring of Heart Failure. <i>Heart Failure Clinics</i> , 2006, 2, 333-343.	1.0	10
101	Noninvasive Calibration of Cardiac Pressure Transducers in Patients With Heart Failure: An Aid to Implantable Hemodynamic Monitoring and Therapeutic Guidance. <i>Journal of Cardiac Failure</i> , 2006, 12, 568-576.	0.7	18
102	Mitral Valve Surgery in the Adult Marfan Syndrome Patient. <i>Annals of Thoracic Surgery</i> , 2006, 81, 843-848.	0.7	41
103	Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients. <i>American Heart Journal</i> , 2006, 152, 312-320.	1.2	23
104	Dynamic Myocardial Ischemia Caused by Circumflex Artery Stenosis Detected by a New Implantable Left Atrial Pressure Monitoring Device. <i>Circulation</i> , 2006, 113, e705-6.	1.6	15
105	NTproBNP-guided drug treatment for chronic heart failure: design and methods in the $\alpha$ BATTLESCARRED trial. <i>European Journal of Heart Failure</i> , 2006, 8, 532-538.	2.9	69
106	Angiotensin Type-1 Receptor A1166C Gene Polymorphism Correlates With Oxidative Stress Levels in Human Heart Failure. <i>Hypertension</i> , 2006, 47, 1155-1161.	1.3	52
107	Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure. <i>Circulation</i> , 2006, 113, 977-985.	1.6	117
108	Plasma B-type natriuretic peptide levels in systolic heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 43, 416-422.	1.2	246

#	ARTICLE	IF	CITATIONS
109	Clinical applications of B-type natriuretic peptides. Trends in Endocrinology and Metabolism, 2004, 15, 170-174.	3.1	14
110	Adrenomedullin and the renin-angiotensin-aldosterone system. Regulatory Peptides, 2003, 112, 41-49.	1.9	34
111	B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction. Circulation, 2003, 107, 2786-2792.	1.6	402
112	Antecedent hypertension and heart failure after myocardial infarction. Journal of the American College of Cardiology, 2002, 39, 1182-1188.	1.2	90
113	BNP in hormone-guided treatment of heart failure. Trends in Endocrinology and Metabolism, 2002, 13, 151-155.	3.1	40
114	Bioactivity of adrenomedullin and proadrenomedullin N-terminal 20 peptide in man. Peptides, 2001, 22, 1745-1752.	1.2	26
115	Brain natriuretic peptide-guided therapy for heart failure. Annals of Medicine, 2001, 33, 422-427.	1.5	26
116	Individualized treatment of heart failure. Internal Medicine Journal, 2001, 31, 138-141.	0.5	9
117	Hypotensive and Natriuretic Actions of Adrenomedullin in Subjects With Chronic Renal Impairment. Hypertension, 2001, 37, 1279-1284.	1.3	40
118	Beneficial Renal and Hemodynamic Effects of Omapatrilat in Mild and Severe Heart Failure. Hypertension, 2000, 36, 523-530.	1.3	45
119	Hemodynamic, Hormone, and Urinary Effects of Adrenomedullin Infusion in Essential Hypertension. Hypertension, 2000, 36, 588-593.	1.3	65
120	Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet, The, 2000, 355, 1126-1130.	6.3	1,272
121	Hemodynamic, Hormonal, and Renal Effects of Short-Term Adrenomedullin Infusion in Healthy Volunteers. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1016-1020.	1.8	68